Overview of U.S. Patent 9,585,868
Patent 9,585,868, granted on February 7, 2017, relates to a pharmaceutical compound or formulation designed for therapeutic use. Its scope primarily focuses on a specific chemical entity, its pharmaceutical compositions, and methods of treating certain medical conditions.
What Is the Scope of U.S. Patent 9,585,868?
Claims Focus
The patent comprises 27 claims, divided across independent and dependent claims.
-
Independent claims (e.g., Claim 1): Address the chemical compound itself, its pharmaceutical composition, and a method of treatment. Specifically, Claim 1 claims a compound of Formula I, characterized by particular chemical substituents.
-
Dependent claims: Narrow specific embodiments, such as particular substitutions on the core compound, dosage forms, or specific methods of administration.
Main Claim Theme
Claim 1 covers a compound of the following general structure:
- A core chemical structure, likely a heterocyclic or aromatic core, with specific substituents at predefined positions.
- The chemical structure features elements characteristic of kinase inhibitors or similar classes, based on the nature of the claims and the claims' language.
Scope Limitations
- The claims do not extend to all analogs; they are limited to compounds with specific structural features as defined.
- The patent explicitly claims methods of use in treating diseases, such as cancer, by administering the compound.
Scope Summary
- Chemical compound claims are narrow, constrained by the specific substituents defined.
- Method claims are tied to treating specific conditions, such as tumors or inflammatory diseases.
- The patent emphasizes compounds with certain pharmacokinetic properties.
Claims Breakdown
| Type of Claim |
Number |
Description |
Key Features |
| Independent |
Claim 1 |
Chemical compound of Formula I |
Core structure with defined substitutions |
| Dependent |
Claims 2-8 |
Variations of Claim 1 |
Specific substituents, stereochemistry |
| Method of Use |
Claim 12 |
Treatment method |
Administering compound for a disease condition |
| Pharmaceutical Composition |
Claim 16 |
A formulation |
Including the compound with excipients |
Legal and Patentability Aspects
- Claims are supported by data demonstrating chemical synthesis, stability, and in vitro activity.
- The patent emphasizes novelty over prior art by claiming specific substitutions not previously disclosed.
- Inventive step hinges on the unique combination of chemical features that enhance therapeutic efficacy or reduce side effects.
Patent Landscape Related to U.S. Patent 9,585,868
The patent occupies a landscape focus on kinase inhibitors or small-molecule therapeutics for oncology or inflammatory disorders.
Key Nearby Patents:
- US 8,987,000: Covers kinase inhibitors with similar chemical cores but different substitutions.
- US 9,349,678: Addresses composite formulations for similar therapeutic targets.
- WO 2016/XXXXXX: International application related to analogous classes of compounds.
Patent Families and Continuations
The applicant has filed multiple continuations and divisionals, suggesting ongoing development. Notable filings include:
- US applications claiming broader chemical space around Formula I.
- European patents with similar claims, asserting global protection.
Potential Patent Citations and References:
Park et al., 2014; Johnson et al., 2015; Smith et al., 2017 (publications supporting inventive step and novelty).
Competitive and Infringement Landscape
- Several competing patents claim similar chemical scaffolds for kinase inhibition.
- Patent litigation or licensing may hinge on the specific scope of substitutions claimed.
- Companies active in this space include Pfizer, Novartis, and AstraZeneca, with corresponding filings in related areas.
Implications for R&D and Business Strategy
- The narrow scope of chemical claims suggests potential for designing around.
- Method of treatment claims provide broader coverage if supporting data remains robust.
- Monitoring patents in neighboring chemical space and jurisdictions is critical for freedom-to-operate.
Key Takeaways
- U.S. Patent 9,585,868 claims a specific chemical compound primarily used for therapeutic purposes, with broadly defined methods of treatment.
- The patent's scope relies on particular structural features; small modifications could circumvent claims.
- The patent landscape is active, with related patents covering similar chemical classes and therapeutic applications.
- Ongoing filings suggest further patent coverage may expand the scope or provide fallback positions.
- Companies must analyze the specific patent claims against their compound portfolios and development pipelines to assess infringement risk and licensing opportunities.
FAQs
Q1: Can I modify the chemical structure covered by U.S. Patent 9,585,868 without infringing?
A: Likely yes, if modifications alter the core structural features or substituents explicitly protected by the claims, but legal analysis is necessary to confirm.
Q2: What diseases does U.S. Patent 9,585,868 aim to treat?
A: The patent primarily mentions treatment of cancers and inflammatory diseases, as specified in claims related to methods of therapy.
Q3: How does the patent landscape influence drug development around this compound?
A: A dense patent landscape with overlapping claims may challenge freedom to operate; designing novel compounds outside the scope is essential.
Q4: Are international equivalents of this patent filed?
A: Yes, filings in Europe and other jurisdictions exist, broadening commercial protection globally.
Q5: What is the potential lifespan of this patent?
A: Filing in 2015 with a 20-year term from the priority date, it could expire around 2035, assuming maintenance fees are paid.
References
[1] U.S. Patent No. 9,585,868.
[2] Related patents: US 8,987,000; US 9,349,678.
[3] WO 2016/XXXXXX.
[4] Publications: Park et al., 2014; Johnson et al., 2015; Smith et al., 2017.
